Adcock Ingram Holdings Limited - Asset Resilience Ratio
Adcock Ingram Holdings Limited (AIP) has an Asset Resilience Ratio of 0.16% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AIP net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Adcock Ingram Holdings Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Adcock Ingram Holdings Limited's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Adcock Ingram Holdings Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Adcock Ingram Holdings Limited strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ZAC0.00 | 0% |
| Short-term Investments | ZAC13.39 Million | 0.16% |
| Total Liquid Assets | ZAC13.39 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Adcock Ingram Holdings Limited maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Adcock Ingram Holdings Limited Industry Peers by Asset Resilience Ratio
Compare Adcock Ingram Holdings Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Adcock Ingram Holdings Limited (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Adcock Ingram Holdings Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.16% | ZAC13.39 Million ≈ $7.12K |
ZAC8.35 Billion ≈ $4.44 Million |
+0.36pp |
| 2023-06-30 | -0.20% | ZAC-16.83 Million ≈ $-8.94K |
ZAC8.26 Billion ≈ $4.39 Million |
-4.29pp |
| 2022-06-30 | 4.08% | ZAC322.14 Million ≈ $171.20K |
ZAC7.89 Billion ≈ $4.19 Million |
+3.34pp |
| 2021-06-30 | 0.74% | ZAC52.32 Million ≈ $27.80K |
ZAC7.04 Billion ≈ $3.74 Million |
-3.07pp |
| 2020-06-30 | 3.82% | ZAC274.10 Million ≈ $145.67K |
ZAC7.18 Billion ≈ $3.82 Million |
-3.35pp |
| 2019-06-30 | 7.17% | ZAC448.25 Million ≈ $238.22K |
ZAC6.25 Billion ≈ $3.32 Million |
+0.72pp |
| 2018-06-30 | 6.45% | ZAC404.63 Million ≈ $215.04K |
ZAC6.27 Billion ≈ $3.33 Million |
-4.19pp |
| 2017-06-30 | 10.64% | ZAC592.07 Million ≈ $314.65K |
ZAC5.56 Billion ≈ $2.96 Million |
+10.60pp |
| 2013-06-30 | 0.04% | ZAC2.73 Million ≈ $1.45K |
ZAC6.82 Billion ≈ $3.62 Million |
-- |
About Adcock Ingram Holdings Limited
Adcock Ingram Holdings Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of healthcare products to private and public sectors in Southern Africa and India. It operates through four segments: Consumer, Over the Counter (OTC), Prescription, and Hospital Products and Services. The company provides various healthcare, personal care, and homecare products… Read more